The incretin glucagon-like peptide1(GLP-1) is mainly produced by L cells in thegutandregulates postprandial blood glucose. Changes ingutmicrobiota composition and function have been observed in obesity and type 2 diabetes (T2D).
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with thegutmicrobiomeremain an emerging frontier in pharmacological and metabolic research.
As we can see from the illustration, Gut Microbiome And Glp-1 Regulation has many fascinating aspects to explore.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used to treat and manage type 2 diabetes mellitus (T2DM) and obesity. The present narrative review explores potential interactions between thegutmicrobiomeandGLP-1RAs.
Functionalmicrobiometesting offers practitioners a valuable lens into thegutenvironment. When interpreted withGLP-1physiology in mind, test results can guide highly personalized strategies to support endogenousGLP-1production. Interventions can be organized across three primary domains: diet, lifestyle, and targeted supplementation.
This particular example perfectly highlights why Gut Microbiome And Glp-1 Regulation is so captivating.
MicrobialregulationofGLP-1secretion Thegutmicrobiomehelps regulateGLP-1, a hormone secreted by enteroendocrine L-cells in the intestine.
In this review, we highlight the current state of the literature that has brought into light the importance ofGLP-1andGLP-2 in orchestrating intestine-microbiota-immune system crosstalk to maintain intestinal barrier integrity, inflammation, and metabolic homeostasis.
A study available on PubMed Central explores this connection, highlighting how thegutmicrobiome'scomposition can influenceGLP-1secretion and overall metabolic health. The research underlines the potential of dietary interventions and probiotics in supportingGLP-1production.
